Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Activity of Combined Flavopiridol and Lenalidomide in Patients with Cytogenetically High Risk Chronic Lymphocytic Leukemia (CLL): Updated Results of a Phase I Trial,

Kristie A. Blum, MD, Lai Wei, Jeffrey A. Jones, MD, MPH, Leslie A Andritsos, MD, Joseph M. Flynn, DO, MPH, Nyla A. Heerema, PhD, Xiaoxia Yang, Darlene Rozewski, Mitchell Phelps, Ph.D., Amy J Johnson, PhD, Michael R. Grever, M.D., John C. Byrd, MD

Blood (2011) 118 (21): 3910.

https://doi.org/10.1182/blood.V118.21.3910.3910

Published: 2011

Journal Articles

Targeting the Cyclin D - CDK4/6 - Rb Axis in Mantle Cell Lymphoma with the Novel Translation Inhibitor Silvestrol,

Lapo Alinari, MD., Ph.D., Ryan B. Edwards, Courtney J. Prince, William H. Towns, Rajeswaran Mani, DVM, Amy Lehman, Xiaoli Zhang, PhD, MS, David Jarjoura, PhD, Li Pan, PhD, A. Douglas Kinghorn, PhD, DSc, Michael R. Grever, M.D., Robert A. Baiocchi, M.D., Ph.D., David M. Lucas, PhD

Blood (2011) 118 (21): 3498.

https://doi.org/10.1182/blood.V118.21.3498.3498

Published: 2011

Journal Articles

Silvestrol Modulates Direct Anti-Tumor Activity Against Epstein-Barr Virus (EBV)-Associated Lymphomas While Sparing Innate and Antigen Specific Adaptive Immunity

John T. Patton, Mark E Lustberg, MD, PhD, Sabrina L Garman, A Douglas Kinghorn, Ph.D., D.Sc, Li Pan, PhD, David M. Lucas, PhD, Michael R. Grever, M.D., Robert A. Baiocchi, M.D., Ph.D.

Blood (2011) 118 (21): 104.

https://doi.org/10.1182/blood.V118.21.104.104

Published: 2011

Journal Articles

Flavopiridol Is An Effective Therapy to Bridge Patients with Chronic Lymphocytic Leukemia (CLL) to Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant

Samantha M. Jaglowski, MD, Joseph M. Flynn, DO, MPH, Jeffrey A. Jones, MD, MPH, Thomas S. Lin, MD, PhD, Beth Fischer, Diane Scholl, Patrick Elder, MS, Steven M. Devine, MD, Michael R. Grever, M.D., John C. Byrd, MD, Leslie Andritsos, MD

Blood (2010) 116 (21): 2383.

https://doi.org/10.1182/blood.V116.21.2383.2383

Published: 2010

Journal Articles

Phase 1 Trial of Flavopiridol and Lenalidomide In Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL)

Kristie A. Blum, MD, Jeffrey A. Jones, MD, MPH, Leslie Andritsos, MD, Joseph M. Flynn, DO, MPH, Deidre Deam, RN, Nyla A. Heerema, PhD, Mitchell Phelps, PhD, Amy J Johnson, PhD, Michael R. Grever, M.D., John C. Byrd, MD

Blood (2010) 116 (21): 2472.

https://doi.org/10.1182/blood.V116.21.2472.2472

Published: 2010

Journal Articles

Interim Analysis of EFC6663, a Multicenter Phase 2 Study of Alvocidib (flavopiridol), Demonstrates Clinical Responses Among Patients with Fludarabine Refractory CLL

Mark C Lanasa, MD, PhD, Leslie Andritsos, MD, Jennifer R Brown, MD, PhD, Janice Gabrilove, M.D., Federico Caligaris-Cappio, M.D., Richard Larson, M.D., Thomas J. Kipps, MD, PhD, Veronique Leblond, M.D., Donald Milligan, MD, FRCP, FRCPath, Ann Janssens, M.D., Nyla A. Heerema, Ph.D., Stephan Stilgenbauer, M.D., John C. Byrd, MD, Michael R. Grever, M.D.

Blood (2010) 116 (21): 58.

https://doi.org/10.1182/blood.V116.21.58.58

Published: 2010

Journal Articles

Early Evidence of Anti-Lymphoma Activity of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH 727965) In Heavily Pre-Treated Low Grade Lymphoma and Diffuse Large Cell Lymphoma Patients

Robert A Baiocchi, MD, PhD, Joseph M. Flynn, DO, MPH, Jeffrey A. Jones, MD, MPH, Kristie A. Blum, MD, Craig C. Hofmeister, MD, Jennifer Poon, PharmD, Karen Small, BSN, Paul Statkevich, PhD, Michael R. Grever, M.D., Rajat Bannerji, MD, PHD, John C. Byrd, MD

Blood (2010) 116 (21): 3966.

https://doi.org/10.1182/blood.V116.21.3966.3966

Published: 2010

Journal Articles

Risk Factors for Tumor Lysis Syndrome (TLS) In Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Cyclin Dependent Kinase Inhibitor, Flavopiridol.

Kristie A. Blum, MD, Amy S. Ruppert, Jennifer A. Woyach, MD, Jeffrey A. Jones, MD, MPH, Leslie Andritsos, MD, Joseph M. Flynn, DO, MPH, Brad Rovin, MD, Miguel Villalona-Calero, MD, Jia Ji, Mitchell Phelps, PhD, Amy J. Johnson, PhD, Michael R. Grever, M.D., John C. Byrd, MD

Blood (2010) 116 (21): 1386.

https://doi.org/10.1182/blood.V116.21.1386.1386

Published: 2010

Journal Articles

Update on the Phase I Study of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH 727965) In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity and Feasibility of Long-Term Administration

Joseph M. Flynn, DO, MPH, Jeffrey A. Jones, MD, MPH, Leslie Andritsos, MD, Kristie A. Blum, MD, Amy J. Johnson, PhD, Josh Hessler, Elizabeth Wiley, Jennifer Poon, PharmD, Karen Small, BSN, Paul Statkevich, PhD, Michael R. Grever, M.D., Rajat Bannerji, MD, PhD, John C. Byrd, MD

Blood (2010) 116 (21): 1396.

https://doi.org/10.1182/blood.V116.21.1396.1396

Published: 2010

Journal Articles

Increased Incidence of Therapy Related Myeloid Neoplasia (t-MN) After Initial Therapy for CLL with Fludarabine-Cyclophosphamide (FC) Vs Fludarabine (F): Long-Term Follow-up of US Intergroup Study E2997

Blood (2010) 116 (21): 924.

https://doi.org/10.1182/blood.V116.21.924.924

Published: 2010

Journal Articles

Dinaciclib (SCH727965) Is a Novel Cyclin Dependent Kinase Inhibitor That Promotes Selective Apoptosis In CLL Cells and Abrogates the Protective Effects of Microenvironment Cytokines

Amy J. Johnson, PhD, Lisa L. Smith, Amy J. Wagner, Joshua Hessler, Joseph M. Flynn, DO, MPH, Jeffrey A. Jones, MD, MPH, Xiaoli Zhang, Amy Lehman, David Jarjoura, Michael R. Grever, M.D., Rajat Bannerji, MD, PHD, John C. Byrd, MD

Blood (2010) 116 (21): 971.

https://doi.org/10.1182/blood.V116.21.971.971

Published: 2010

Journal Articles

Autophagy Is a Relevant Cellular Process In CLL and Contributes to Drug Resistance of Flavopiridol

Emilia Mahoney, MD, PhD, Amy J. Johnson, PhD, Amy J. Wagner, Joshua Hessler, Sneha V. Gupta, Sarah E.M. Herman, Leslie Andritsos, MD, Jeffrey A. Jones, MD, MPH, Joseph M. Flynn, DO, MPH, David M. Lucas, PhD, Michael R. Grever, M.D., John C. Byrd, MD

Blood (2010) 116 (21): 691.

https://doi.org/10.1182/blood.V116.21.691.691

Published: 2010

Journal Articles

Flavopiridol Can Be Safely Administered Using a Pharmacologically Derived Schedule and Demonstrates Activity In Relapsed and Refractory Non-Hodgkin's Lymphoma.

Jeffrey A. Jones, MD, MPH, Leslie Andritsos, MD, Robert Baiocchi, MD, PhD, Don M Benson, Jr., MD, PhD, Kristie A. Blum, MD, Beth Christian, MD, Deidre Deam, RN, Joseph M. Flynn, DO, MPH, Amy J. Johnson, PhD, Mitch A. Phelps, PhD, Pierluigi Porcu, MD, John C. Byrd, MD, Michael R. Grever, M.D.

Blood (2010) 116 (21): 2834.

https://doi.org/10.1182/blood.V116.21.2834.2834

Published: 2010

Journal Articles

Quantification of Intracellular Decitabine-Triphosphate with A Novel, Highly Sensitive and Specific LC-MS/MS Assay in Acute Myeloid Leukemia Patients Treated with Low Dose Decitabine.

Ping Chen, Ph.D., William Blum, M.D., Josephine Aimiuwu, B.S., Vijayasarathi Upadhyayula, Ph.D., Zhongfa Liu, Ph.D., Shujun Liu, Ph.D., Jiuxia Pang, B.S., Alison Walker, M.D., Rebecca B. Klisovic, M.D., Ramiro Garzon, M.D., Michael R. Grever, M.D., Miguel Villalona-Calero, M.D., John C. Byrd, M.D., Kenneth K Chan, Ph.D., Guido Marcucci, M.D.

Blood (2009) 114 (22): 3782.

https://doi.org/10.1182/blood.V114.22.3782.3782

Published: 2009

Journal Articles

del(17p13.1) in Chronic Lymphocytic Leukemia Confers Poor Prognosis Even at Low Percentage Involvement and Increases Proportionately with Increase in Clonal Involvement.

Leslie A. Andritsos, MD, Jeffrey Jones, M.D., Gerard Lozanski, M.D., Thomas S. Lin, M.D., Kristie A. Blum, M.D., Michael R. Grever, M.D., David Jarjoura, Ph.D., John C. Byrd, M.D., Nyla Heerema, M.D.

Blood (2007) 110 (11): 2073.

https://doi.org/10.1182/blood.V110.11.2073.2073

Published: 2007

Journal Articles

Low Incidence of Opportunistic Infections in CLL Patients Treated with Single Agent Flavopiridol.

Leslie A. Andritsos, MD, Beth Fischer, R.N., Thomas S. Lin, M.D., Kristie A. Blum, M.D., Jeffrey A. Jones, M.D., Mollie E. Moran, C.N.P., John C. Byrd, M.D., Michael R. Grever, M.D.

Blood (2007) 110 (11): 3128.

https://doi.org/10.1182/blood.V110.11.3128.3128

Published: 2007

Journal Articles

Decitabine-Induced Differentiation Syndrome in a Patient with Acute Myeloid Leukemia: A Case Report.

William Blum, M.D., Kristie A. Blum, M.D., Cheryl Kefauver, R.N., Mollie Moran, C.R.N.P., Kenneth Chan, Ph.D., John C. Byrd, M.D., Spero Cataland, M.D., Michael R. Grever, M.D., Guido Marcucci, M.D.

Blood (2004) 104 (11): 4528.

https://doi.org/10.1182/blood.V104.11.4528.4528

Published: 2004

NARROW

Activity of Combined Flavopiridol and Lenalidomide in Patients with Cytogenetically High Risk Chronic Lymphocytic Leukemia (CLL): Updated Results of a Phase I Trial,

Targeting the Cyclin D - CDK4/6 - Rb Axis in Mantle Cell Lymphoma with the Novel Translation Inhibitor Silvestrol,

Silvestrol Modulates Direct Anti-Tumor Activity Against Epstein-Barr Virus (EBV)-Associated Lymphomas While Sparing Innate and Antigen Specific Adaptive Immunity

Flavopiridol Is An Effective Therapy to Bridge Patients with Chronic Lymphocytic Leukemia (CLL) to Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant

Phase 1 Trial of Flavopiridol and Lenalidomide In Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL)

Interim Analysis of EFC6663, a Multicenter Phase 2 Study of Alvocidib (flavopiridol), Demonstrates Clinical Responses Among Patients with Fludarabine Refractory CLL

Early Evidence of Anti-Lymphoma Activity of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH 727965) In Heavily Pre-Treated Low Grade Lymphoma and Diffuse Large Cell Lymphoma Patients

Risk Factors for Tumor Lysis Syndrome (TLS) In Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Cyclin Dependent Kinase Inhibitor, Flavopiridol.

Update on the Phase I Study of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH 727965) In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity and Feasibility of Long-Term Administration

Increased Incidence of Therapy Related Myeloid Neoplasia (t-MN) After Initial Therapy for CLL with Fludarabine-Cyclophosphamide (FC) Vs Fludarabine (F): Long-Term Follow-up of US Intergroup Study E2997

Dinaciclib (SCH727965) Is a Novel Cyclin Dependent Kinase Inhibitor That Promotes Selective Apoptosis In CLL Cells and Abrogates the Protective Effects of Microenvironment Cytokines

Autophagy Is a Relevant Cellular Process In CLL and Contributes to Drug Resistance of Flavopiridol

Flavopiridol Can Be Safely Administered Using a Pharmacologically Derived Schedule and Demonstrates Activity In Relapsed and Refractory Non-Hodgkin's Lymphoma.

Quantification of Intracellular Decitabine-Triphosphate with A Novel, Highly Sensitive and Specific LC-MS/MS Assay in Acute Myeloid Leukemia Patients Treated with Low Dose Decitabine.

del(17p13.1) in Chronic Lymphocytic Leukemia Confers Poor Prognosis Even at Low Percentage Involvement and Increases Proportionately with Increase in Clonal Involvement.

Low Incidence of Opportunistic Infections in CLL Patients Treated with Single Agent Flavopiridol.

Decitabine-Induced Differentiation Syndrome in a Patient with Acute Myeloid Leukemia: A Case Report.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only